Genetic abnormalities specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization

被引:27
作者
Chu, LW
Pettaway, CA
Liang, JC
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
关键词
D O I
10.1016/S0165-4608(01)00389-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Established recently are two in vivo prostate tumor progression models in which subclones of the PC3M and LNCaP cell lines were selected for varying growth characteristics and metastatic potential after successive orthotopic implantation in the prostate of nude mice. In this study, we used comparative genomic hybridization (CGH) to compare the chromosomal abnormalities between the parental cell lines and their respective variants and to determine if specific chromosomal abnormalities can be identified that are associated with different growth properties. PC3M and its derivative cell lines PC3M-Pro4 and PC3M-LN4 shared gains of 8q22-qter, 10q21-q22. and Xq27-qter and loss of 13q33-qter. PC3M-Pro4, a derivative line that produced significantly larger tumors in the prostate, had a unique gain of 3q13. In contrast, PC3M-LN4. the derivative line that produced significantly larger metastatic tumors in the lymph nodes and had higher incidences of distant metastases, had a specific gain of 1q21-q22 and losses of 10q23-qter and 18q12-q21. In the second in vivo model. LNCaP and its derivative cell lines shared gain of 3q27-qter and loss on 13q21-qter. The derivative line that produced significantly larger tumors in the prostate. LNCaP-Pro5, had a unique gain on 13q12-q13. In comparison, LNCaP-LN3. a derivative line that had a significantly higher incidence of lymph node metastases and produced significantly larger metastatic tumors in the lymph nodes. had specific losses of 16q23-qter and 21q. Interestingly, some regions of loss (e.g., 10q23 --> qter. 16q23 --> qter. and 18q12 --> q21) detected in the variant cell lines correlated well with abnormalities seen in clinical prostate cancer cases. Thus, our data suggest not only that these cell lines are relevant in vivo models for prostate cancer progression, but also that CGH is a valuable tool for uncovering chromosomal regions that are important for aggressive growth and metastsis of prostate cancer cells. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 43 条
  • [11] Three independently deleted regions at chromosome arm 16q in human prostate cancer:: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient
    Elo, JP
    Härkönen, P
    Kyllönen, AP
    Lukkarinen, O
    Vihko, P
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (01) : 156 - 160
  • [12] Androgen-induced proliferative quiescence in prostate cancer cells: The role of AS3 as its mediator
    Geck, P
    Maffini, MV
    Szelei, J
    Sonnenschein, C
    Soto, AM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (18) : 10185 - 10190
  • [13] Hahn M, 1999, CLIN CANCER RES, V5, P2431
  • [14] Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model
    Hyytinen, ER
    Thalmann, GN
    Zhau, HE
    Karhu, R
    Kallioniemi, OP
    Chung, LWK
    Visakorpi, T
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (02) : 190 - 195
  • [15] Ittmann MM, 1998, ONCOL REP, V5, P1329
  • [16] Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.3.CO
  • [17] 2-E
  • [18] KAIGHN ME, 1979, INVEST UROL, V17, P16
  • [19] COMPARATIVE GENOMIC HYBRIDIZATION FOR MOLECULAR CYTOGENETIC ANALYSIS OF SOLID TUMORS
    KALLIONIEMI, A
    KALLIONIEMI, OP
    SUDAR, D
    RUTOVITZ, D
    GRAY, JW
    WALDMAN, F
    PINKEL, D
    [J]. SCIENCE, 1992, 258 (5083) : 818 - 821
  • [20] KOSLOWSKI J, 1984, CANCER RES, V44, P3522